Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma

Published:2017-05-26 Issue:8 Volume:102 Page:2922-2929
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Beukhof Carolien M¹,van Doorn Leni²,Visser Theo J¹,Bins Sander²,Visser W Edward¹,van Heerebeek Ramona¹,van Kemenade Folkert J³,de Rijke Yolanda B⁴,de Herder Wouter W¹,Chaker Layal¹⁵,Mathijssen Ron H²,Peeters Robin P¹

Affiliation:

1. Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands

2. Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands

3. Department of Pathology, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands

4. Department of Clinical Chemistry, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands

5. Department of Epidemiology, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/102/8/2922/19452616/jc.2016-4025.pdf

Reference40 articles.

1. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis;Makita;Thyroid,2013

2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

3. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

4. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial;Brose;Lancet,2014

5. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling;Wilhelm;Mol Cancer Ther,2008

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05

2. Immune-related adverse events of cancer immunotherapies targeting kinases;Pharmacology & Therapeutics;2022-09

3. High-throughput Screening in Combination With a Cohort Study for Iodothyronine Deiodinases;Endocrinology;2022-06-13

4. Thyroid Dysfunction from Treatments for Solid Organ Cancers;Endocrinology and Metabolism Clinics of North America;2022-06

5. A decrease in peripheral thyroid hormone conversion efficiency in patients treated with immune checkpoint inhibitors and L‐T3 as a possible alternative therapeutic escape option;European Journal of Clinical Investigation;2022-04-21